Effects of PreOperative radiotherapy in a preclinical glioblastoma model: a paradigm-shift approach.

Abstract

PURPOSE: PreOperative radiotherapy (RT) is commonly used in the treatment of brain metastasis and different cancer types but has never been used in primary glioblastoma (GBM). Here, we aim to establish, describe, and validate the use of PreOperative RT for the treatment of GBM in a preclinical model. METHODS: Rat brains were locally irradiated with 30-Gy, hypofractionated in five doses 2 weeks before or after the resection of intracranial GBM. Kaplan-Meier analysis determined survival. Hematoxylin-eosin staining was performed, and nuclei size and p21 senescence marker were measured in both resected and recurrent rodent tumors. Immunohistochemistry assessed microglia/macrophage markers, and RNAseq analyzed gene expression changes in recurrent tumors. Akoya Multiplex Staining on two human patients from our ongoing Phase I/IIa trial served as proof of principle. RESULTS: PreOperative RT group median survival was significantly higher than PostOperative RT (p&#x2009;<&#x2009;0.05). Radiation enlarged cytoplasm and nuclei in PreOperative RT resected tumors (p&#x2009;<&#x2009;0.001) and induced senescence in PostOperative RT recurrent tumors (p&#x2009;<&#x2009;0.05). Gene Set Enrichment Analysis (GSEA) suggested a more proliferative profile in PreOperative RT group. PreOperative RT showed lower macrophage/microglia recruitment in recurrent tumors (p&#x2009;<&#x2009;0.01) compared to PostOperative RT. Akoya Multiplex results indicated TGF-&#xdf; accumulation in the cytoplasm of TAMs and CD4&#x2009;+&#x2009;lymphocyte predominance in PostOperative group. CONCLUSIONS: This is the first preclinical study showing feasibility and longer overall survival using neoadjuvant radiotherapy before GBM resection in a mammalian model. This suggests strong superiority for new clinical radiation strategies. Further studies and trials are required to confirm our results.